-
Mashup Score: 25Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy - 7 day(s) ago
Feasibility trial comparing immunoglobulin and prophylactic antibiotics in patients with hypogammaglobulinemia due to blood cancers.A similar proportion of
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Optimizing initial therapy of CLL - 6 month(s) ago
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the specific considerations for optimizing chronic lymphocytic leukemia (CLL) treatment in patients in the frontline setting. These include age, comorbidities, length of treatment (time-limited or continuous), and access to lines of therapy. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6Real-world safety and efficacy of first- and second-generation BTK inhibitors in CLL - 6 month(s) ago
Raul Cordoba, MD, PhD, Fundación Jiménez DÃaz, Madrid, Spain, discusses the real-world safety and efficacy of first-and second-generation BTK inhibitors used to treat patients with chronic lymphocytic leukemia (CLL), including ibrutinib and acalabrutinib. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
7500 Background: The Bruton’s tyrosine kinase inhibitor (BTKi) ibrutinib +/- anti-CD20 antibody obinutuzumab (IO) is a standard frontline regimen for older adults with CLL. BTKi alone do not often lead to complete response (CR) or undetectable minimal residual disease (uMRD), thus are given indefinitely. Smaller trials showed that IO plus venetoclax (IVO) can induce uMRD CRs which may allow successful discontinuation. Methods: Alliance for Clinical Trials in Oncology A041702 is a multicenter trial designed to evaluate if IVO with response-guided discontinuation of I improves progression free survival (PFS) versus IO with indefinite I in treatment-naïve, older CLL pts. IO is given in standard fashion, and in the IVO arm V is added at C3D1 and continued until C14D28. After 14 cycles, pts undergo response evaluation including CT scans and bone marrow biopsy with central MRD assessment by flow cytometry. Pts in IVO arm with uMRD CR discontinue I; all others continue I until progression or
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses results from the EPCORE CLL-1 trial (NCT04623541), which is evaluating the safety and efficacy of epcoritamab in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0iwCLL 2023 | VJHemOnc - 6 month(s) ago
The biennial International Workshop on Chronic Lymphocytic Leukemia TM (XX iwCLL 2023) will be held in Boston, MA, from October 6-9, 2023, and will be an opportunity for international hemonc leaders from all over the world to discuss the latest updates in the pathobiology and treatment of CLL. The biennial International Workshop on Chronic Lymphocytic Leukemia TM (XX iwCLL 2023) will be hel d in Boston, MA, from October 6-9, 2023, and will be an opportunity for international hemonc leaders from all over
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Choosing between continuous versus fixed-duration therapy in CLL - 6 month(s) ago
In this video, Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses factors to consider when selecting between continuous and fixed-duration therapy in chronic lymphocytic leukemia (CLL), including presence of TP53 mutation, patient preference, and other comorbidities. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA - 7 month(s) ago
Adam Kittai, MD, Ohio State University, Columbus, OH, shares some insights into a matching-adjusted indirect comparison (MAIC) conducted using patient data from the SEQUOIA and ELEVATE-TN trials (NCT03336333; NCT02475681). Dr Kittai gives an overview of these two trials and the statistical methods used in the MAIC, and further discusses the main findings. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0iwCLL 2023 | VJHemOnc - 7 month(s) ago
The biennial International Workshop on Chronic Lymphocytic Leukemia TM (XX iwCLL 2023) will be held in Boston, MA, from October 6-9, 2023, and will be an opportunity for international hemonc leaders from all over the world to discuss the latest updates in the pathobiology and treatment of CLL. The biennial International Workshop on Chronic Lymphocytic Leukemia TM (XX iwCLL 2023) will be hel d in Boston, MA, from October 6-9, 2023, and will be an opportunity for international hemonc leaders from all over
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VJHemOnc – The video journal of hematological oncology - 7 month(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Would love to see a larger trial but encouraging results from this small feasibility study: Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy #cllsm https://t.co/J6BDn6dfrg